Welcome to our dedicated page for Bico Group Publ news (Ticker: BCCOY), a resource for investors and traders seeking the latest updates and insights on Bico Group Publ stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Bico Group Publ's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Bico Group Publ's position in the market.
Lineage Cell Therapeutics has expanded its collaboration with Advanced BioMatrix to include clinical-grade HyStem technology supply for cell therapies. The amended agreement increases milestone payments and royalties for Lineage, enhancing potential revenue streams. CEO Brian M. Culley emphasized a focus on business development and monetizing their technology platform. HyStem, a patented hydrogel, supports various cell types and is crucial for cell functionality. With clinical programs targeting significant market opportunities, this partnership positions Lineage for improved cash flow and supports its development pipeline.
Biosero, Inc., a BICO company, has received a pivotal patent for its Green Button Go® Scheduler, enhancing laboratory automation capabilities. The patent, titled “Automated Control of Multi-Process Using Robotic Equipment for Complex Workflows,” introduces the Multipath Scheduler, allowing simultaneous scheduling of labware transportation using various robot arms and systems. This innovation promotes productivity and operational flexibility in labs, enabling complex workflows to be managed efficiently. This patent signifies a critical milestone in driving the Bioconvergence Revolution.
CollPlant Biotechnologies and CELLINK announced a collaboration agreement on Feb. 16, 2022, to develop large-scale production of regenerative breast implants using CELLINK's 3D bioprinting technology. This collaboration targets a market worth $2.8 billion with approximately 2.2 million procedures conducted annually. CollPlant has produced prototypes of these implants, designed to naturally regenerate breast tissue. CELLINK's expertise in biofabrication is expected to assist in overcoming production challenges, aiming for commercialization to provide essential solutions for patients worldwide.
BICO Group AB has announced its acquisition of QInstruments GmbH for a total of 61.25 million euro, structured as a cash- and debt-free transaction. BICO will pay 3 million euro based on revenue and EBITDA milestones, with approximately 13% of the purchase price in newly issued shares. Founded in 2003, QInstruments specializes in advanced sample preparation automation and is projected to achieve 10.8 million euro in net sales with a 45% EBIT margin in 2021. The acquisition aims to enhance BICO's product offerings in the Bio Convergence sector while allowing QInstruments to operate independently under BICO's umbrella.
FAQ
What is the market cap of Bico Group Publ (BCCOY)?
